Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD vs Epirubicin in Primary Lymphoma
NCT02526823Phase 4Unknown
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Aug 2015
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 4 trial of doxorubicin in non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), peripheral T-cell lymphoma (PTCL), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Status: unknown.
02
Drugs
doxorubicin
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02526823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02526823.